ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES

Avalable online at: http://www.iajps.com *Review Article*

OVERVIEW OF IRON DEFICIENCY ANEMIA

Fatimah Mohammed Al-Hay, Manal Taher AlAli, Kholoud Hassan ALMarhoun
Imam Abdulrahman Bin Faisal Hospital - National Guard - Dammam

Abstract:
Iron deficiency anemia (IDA) is a prevalent nutritional disorder affecting approximately 30% of the global population, particularly in underdeveloped regions. It arises from various causes, including inadequate dietary intake, malabsorption, and chronic blood loss, with specific populations such as pregnant women and young children being at higher risk. Understanding the underlying causes is crucial for effective management, which often involves iron supplementation and addressing any contributing health issues.

Corresponding Author
Fatimah Mohammed Al-Hay,
Imam Abdulrahman Bin Faisal Hospital - National Guard - Dammam

INTRODUCTION:

Iron deficiency anemia (IDA) is a specific classification of anemia characterized by low iron stores and a hemoglobin level that is two standard deviations below normal. This condition is the most prevalent nutritional disorder globally, accounting for approximately half of all anemia cases. The diagnosis of IDA is confirmed through laboratory findings that reveal both low iron stores and the aforementioned hemoglobin level. (1, 2) IDA is classically described as a microcytic anemia, which means that the red blood cells produced are smaller than normal. This classification is significant because it helps differentiate IDA from other types of anemia, such as macrocytic or normocytic anemia, which are characterized by larger or normally sized red blood cells, respectively. (3) The differential diagnosis for microcytic anemia includes conditions such as thalassemia, sideroblastic anemias, and lead poisoning, highlighting the importance of accurate classification in guiding treatment.(3) The underlying causes of iron deficiency can vary, including prolonged intake of diets low in iron, increased iron requirements during pregnancy and lactation, blood loss, and gastrointestinal malabsorption. (1-3) Risk factors for developing IDA include heavy menstrual bleeding and certain gastrointestinal conditions that impair iron absorption. To address IDA, treatment typically involves iron supplementation, often in the form of ferrous sulfate, to restore iron levels in the body.(3) This approach is particularly crucial during periods of increased iron demand, such as pregnancy and early childhood. (4) Additionally, dietary modifications to include iron-rich foods—such as red meat, poultry, fish, beans, lentils, and iron-fortified cereals—are essential for both prevention and management of iron deficiency.

Pathophysiology of Anemia

IDA characterized by insufficient iron supply for erythropoiesis, leading to reduced hemoglobin production and microcytic, hypochromic red blood cells. (4-6) The pathophysiology of IDA primarily stems from inadequate dietary iron intake, impaired absorption, chronic blood loss, and increased physiological demand, particularly during periods of rapid growth such as infancy and puberty. Inadequate iron supply disrupts erythropoiesis, the process of red blood cell production, which is heavily reliant on sufficient iron levels for hemoglobin synthesis. The clinical manifestations of IDA can be subtle, but if left untreated, severe and prolonged anemia may lead to irreversible delayed psychomotor development, especially in children. (6) Iron deficiency is particularly widespread in poorer countries, where dietary sources of bioavailable iron are limited, and among women who experience greater iron losses due to menstruation and childbirth. (5) In developed nations, IDA in men is often attributed to pathological blood loss, which can arise from gastrointestinal issues. (7, 8) Chronic blood loss is a significant contributor to IDA, as it leads to a gradual depletion of iron stores necessary for maintaining adequate hemoglobin levels. (8) These indicators are crucial for diagnosing IDA and differentiating it from other types of anemia. Despite the condition being easily correctable with iron supplementation, identifying the underlying cause can be challenging, particularly in cases related to disorders of iron transport. (5, 7)

Diagnosis of Anemia

The diagnosis of IDA is primarily confirmed through laboratory findings that indicate low iron stores and a hemoglobin level that is two standard deviations below normal .IDA is the most prevalent nutritional disorder globally, accounting for approximately half of all anemia cases. (1, 2, 5) The diagnostic process typically involves assessing serum ferritin, mean corpuscular volume (MCV), and iron saturation, which together form a reliable algorithm for identifying iron deficiency without the need for invasive marrow sampling. (9) Serum ferritin is considered a gold standard for measuring iron deficiency, as it reflects the body's iron stores. (10) In patients with rheumatoid arthritis (RA), for instance, significantly lower levels of serum ferritin, MCV, and iron saturation have been observed, indicating iron deficiency. The algorithm developed in studies has shown a high accuracy rate, correctly classifying 94% of patients with iron deficiency and 85% with anemia of chronic disorders (ACD). This distinction is crucial, as ACD can mimic IDA, complicating the diagnosis. (9) In addition to serum ferritin, MCV serves as a critical measure, as a lower MCV indicates smaller red blood cells, which is often associated with iron deficiency. (9, 10) Furthermore, the red cell distribution width (RDW-CV%) can help detect variability in red blood cell size, providing additional insight into potential deficiencies. (10) Elevated total iron-binding capacity (TIBC) is another indicator that can suggest iron deficiency anemia, as it reflects the blood's capacity to bind iron with transferrin. (11) It is essential to consider the multifactorial nature of iron deficiency, which can arise from inadequate dietary intake, increased physiological demands (such as during pregnancy), blood loss, or gastrointestinal malabsorption. (1, 2, 5) Despite the straightforward nature of iron therapy for correcting IDA, identifying the underlying cause remains a challenge, particularly in cases related to disorders of iron transport.

Conventional Treatment Approaches

IDA necessitating effective treatment strategies to replenish iron stores and improve patient outcomes. The primary approaches to treating IDA include oral iron therapy, parenteral therapy, and dietary modifications. Oral iron therapy is often the first-line treatment for patients who can tolerate it. This method involves administering iron supplements, typically in the form of tablets or capsules, to increase iron levels in the body. However, its effectiveness can be limited by gastrointestinal side effects and absorption issues, which may affect patient compliance. Despite these challenges, oral iron remains a common choice, especially for less severe cases of IDA. For patients who cannot tolerate oral iron or have conditions that impair absorption, parenteral therapy is recommended. This approach allows for iron to be administered directly into the bloodstream, bypassing gastrointestinal limitations. Intravenous iron therapy is particularly beneficial for patients with significant iron deficits or those experiencing severe anemia. Studies have shown that higher cumulative doses of intravenous iron, such as 1500 mg, may be necessary for effective repletion compared to the standard 1000 mg dose, which may be insufficient for many patients. (1, 12) In addition to iron supplementation, dietary modifications can play a crucial role in managing IDA. Incorporating iron-rich foods, such as red meat, beans, and leafy greens, can help improve iron levels naturally. Furthermore, vitamin C supplementation is often recommended alongside iron therapy to enhance iron absorption from the gastrointestinal tract, although its impact on hemoglobin levels may vary. (13) In severe cases of IDA, particularly in patients with chronic kidney disease or those undergoing chemotherapy, erythropoiesis-stimulating agents (ESAs) like rHuEPO (e.g., EPREX) can be combined with intravenous iron therapy to stimulate red blood cell production. (12, 14) This combination approach has been shown to improve hemoglobin levels and reduce the need for blood transfusions in affected patients.

CONCLUSION:

iron deficiency anemia is characterized by diminished iron reserves and markedly low hemoglobin levels, classifying it as microcytic anemia. Accurate diagnosis requires an amalgamation of laboratory assessments, while treatment necessitates a tailored strategy encompassing iron supplementation and dietary adjustments to optimize iron absorption.

REFERENCES:

1. Short MW, Domagalski JE. Iron deficiency anemia: evaluation and management. American family physician. 2013;87(2):98-104.
2. Brady PG. Iron deficiency anemia: a call for aggressive diagnostic evaluation. Southern medical journal. 2007;100(10):966-7.
3. Meeks GR, Gookin KS, Morrison JC. Iron Deficiency Anemia. In: Gleicher N, editor. Principles of Medical Therapy in Pregnancy. Boston, MA: Springer US; 1985. p. 1177-9.
4. Whittaker P. Iron Deficiency and Its Prevention. In: Quah SR, editor. International Encyclopedia of Public Health (Second Edition). Oxford: Academic Press; 2017. p. 342-5.
5. Kaya Z. Iron deficiency anemia: current strategies for the diagnosis and management. Reviews in Health Care. 2013;4(3):193-202.
6. Leung AK, Chan KW. Iron deficiency anemia. Advances in pediatrics. 2001;48(1):385-408.
7. Worwood M. 26 - Disorders of Iron Metabolism. In: Williams DL, Marks V, editors. Scientific Foundations of Biochemistry in Clinical Practice (Second Edition): Butterworth-Heinemann; 1994. p. 446-52.
8. Naigamwalla DZ, Webb JA, Giger U. Iron deficiency anemia. The Canadian Veterinary Journal. 2012;53(3):250.
9. Mulherin D, Skelly M, Saunders A, McCarthy D, O'Donoghue D, Fitzgerald O, et al. The diagnosis of iron deficiency in patients with rheumatoid arthritis and anemia: an algorithm using simple laboratory measures. The Journal of Rheumatology. 1996;23(2):237-40.
10. Dugdale AE. Diagnosis and management of iron deficiency anaemia: a clinical update. The Medical Journal of Australia. 2011;194(8):429.
11. Ogawa H, Nitta K, Nakazawa N, Maki K. Method for determining the total iron-binding capacity of blood serum. Google Patents; 1975.
12. Schaefer R, Huch R, Krafft A. Current recommendations for the treatment of iron deficiency anemia. Revue Médicale Suisse. 2007;3(105):874-80.
13. Cook J, Watson S, Simpson K, Lipschitz D, Skikne B. The effect of high ascorbic acid supplementation on body iron stores. Blood. 1984;64(3):721-6.
14. Macdougall IC. Erythropoiesis-Stimulating Agent Therapy. Pocket Reference to Renal Anemia. Tarporley: Springer Healthcare Ltd.; 2013. p. 29-43.